NECLIFE

NECTAR LIFESCIENCES

Small Cap BSE: 532649 NSE: NECLIFE
₹21.8
-0.65 (-2.9%)
As on 10 December, 2022 | 14:27

Nectar Lifesciences Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in NECTAR LIFESCIENCES

Start SIP

Nectar Lifesciences Share Price

Nectar Lifesciences Share Returns

  • Over 1 Month 2.59%
  • Over 3 Month -9.73%
  • Over 6 Month -12.8%
  • Over 1 Year -16.48%

Nectar Lifesciences Key Statistics

P/E Ratio 173.4
PEG Ratio 1.6
Market Cap Cr 489
Price to Book Ratio 0.4
EPS 0.7
Dividend 0
Relative Strength Index 53.3
Money Flow Index 69.96
MACD Signal 0.1
Average True Range 0.84

Nectar Lifesciences Investment Rating

  • Master Rating:
  • Nectar Lifesciences has an operating revenue of Rs. 1,710.90 Cr. on a trailing 12-month basis. An annual revenue growth of 9% is good, Pre-tax margin of 2% needs improvement, ROE of 2% is fair but needs improvement. The company has a reasonable debt to equity of 27%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 27 which is a POOR score indicating inconsistency in earnings, a RS Rating of 17 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 112 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of E is the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Nectar Lifesciences Financials
IndicatorSep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 389403476443365384349
Operating Expenses Qtr Cr 396361427396337349320
Operating Profit Qtr Cr -7424947273629
Depreciation Qtr Cr 15151414141415
Interest Qtr Cr 21211718182626
Tax Qtr Cr -10265-1-15
Net Profit Qtr Cr -224121022-41

Nectar Lifesciences Technicals

EMA & SMA

Current Price
21.8
-0.65 (-2.9%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 21.57
  • 50 Day
  • 21.65
  • 100 Day
  • 22.45
  • 200 Day
  • 23.94
  • 20 Day
  • 21.16
  • 50 Day
  • 21.32
  • 100 Day
  • 22.49
  • 200 Day
  • 24.33

Nectar Lifesciences Resistance and Support

PIVOT
₹22.57
Resistance
First Resistance 22.84
Second Resistance 23.22
Third Resistance 23.49
RSI 53.3
MFI 69.96
MACD Single Line 0.1
MACD 0.32
Support
First Resistance 22.19
Second Resistance 21.92
Third Resistance 21.54

Nectar Lifesciences Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 332,939 17,649,096 53.01
Week 550,034 33,299,083 60.54
1 Month 318,143 19,476,698 61.22
6 Month 246,411 15,149,375 61.48

Nectar Lifesciences Result Highlights

Nectar Lifesciences Synopsis

NSE-Medical-Generic Drugs

Nectar Lifesciences is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1668.23 Cr. and Equity Capital is Rs. 22.43 Cr. for the Year ended 31/03/2022. Nectar Lifesciences Ltd. is a Public Limited Listed company incorporated on 27/06/1995 and has its registered office in the State of Punjab, India. Company’s Corporate Identification Number(CIN) is L24232PB1995PLC016664 and registration number is 016664.
Market Cap 489
Sales 1,711
Shares in Float 12.56
No of funds 6
Yield 0.22
Book Value 0.45
U/D Vol ratio 1
LTDebt / Equity 27
Alpha -0.08
Beta 1.31

Nectar Lifesciences

Owner NameSep-22Jun-22Mar-22Dec-21
Promoters 55.8%55.8%55.8%
Mutual Funds
Foreign Portfolio Investors 1.53%1.49%1.67%
Individual Investors 24.34%24.2%23.83%
Others 18.33%18.51%18.7%

Nectar Lifesciences Management

Name Designation
Mr. Sanjiv Goyal Chairman & Managing Director
Dr. Kuldip Kumar Bhasin Independent Director
Dr. Indu Pal Kaur Independent Director
Mr. Ajay Swaroop Independent Director
Dr. Rupinder Tewari Independent Director
Ms. Meena Verma Nominee Director

Nectar Lifesciences Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Nectar Lifesciences Corporate Action

Date Purpose Remarks
2022-11-14 Quarterly Results
2022-08-13 Quarterly Results
2022-05-30 Audited Results
2022-02-14 Quarterly Results
2021-11-13 Quarterly Results

Nectar Lifesciences MF Shareholding

Name Amount(cr)
Motilal Oswal S&P BSE Healthcare ETF 6

Nectar Lifesciences FAQs

What is Share Price of Nectar Lifesciences ?

Nectar Lifesciences share price is ₹21 As on 10 December, 2022 | 14:13

What is the Market Cap of Nectar Lifesciences ?

The Market Cap of Nectar Lifesciences is ₹488.9 Cr As on 10 December, 2022 | 14:13

What is the P/E ratio of Nectar Lifesciences ?

The P/E ratio of Nectar Lifesciences is 173.4 As on 10 December, 2022 | 14:13

What is the PB ratio of Nectar Lifesciences ?

The PB ratio of Nectar Lifesciences is 0.4 As on 10 December, 2022 | 14:13

Q2FY23